Cardiac magnetic resonance imaging findings predict major adverse events in apical hypertrophic cardiomyopathy

Journal of Thoracic Imaging

Volumn 29, Issue 6, 2014, Pages 331-339

  Hanneman, Kate ^a   Crean, Andrew M ^a,b   Williams, Lynne ^b   Moshonov, Hadas ^a   James, Susan ^a   Jiménez Juan, Laura ^a   Gruner, Christiane ^b   Sparrow, Patrick ^a   Rakowski, Harry ^b   Nguyen, Elsie T ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apical hypertrophic cardiomyopathy; Cardiac magnetic resonance imaging; Hypertrophic cardiomyopathy; Late gadolinium enhancement

Indexed keywords

GADOBUTROL; GADOLINIUM PENTETATE MEGLUMINE; CONTRAST MEDIUM; ORGANOMETALLIC COMPOUND;

ADULT; ARTICLE; CARDIAC IMAGING; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW UP; HEART ANEURYSM; HEART ATRIUM THROMBOSIS; HEART FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR DISCHARGE; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE COMPLICATION; NUCLEAR MAGNETIC RESONANCE SCANNER; PREDICTIVE VALUE; PROGNOSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SUDDEN CARDIAC DEATH; CARDIOMYOPATHY, HYPERTROPHIC; DIAGNOSTIC USE; HEART MUSCLE; IMAGE ENHANCEMENT; IMAGE PROCESSING; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OBSERVER VARIATION; PATHOLOGY; PROCEDURES; RISK FACTOR;

CARDIOMYOPATHY, HYPERTROPHIC; CONTRAST MEDIA; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIUM; OBSERVER VARIATION; ORGANOMETALLIC COMPOUNDS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84918546986     PISSN: 08835993     EISSN: 15360237     Source Type: Journal    
DOI: 10.1097/RTI.0000000000000115     Document Type: Article

References (40)

1. Hughes SE. The pathology of hypertrophic cardiomyopathy. Histopathology. 2004;44:412-427.
2. Yamaguchi H, Ishimura T, Nishiyama S, et al. Hypertrophic nonobstructive cardiomyopathy with giant negative T waves (apical hypertrophy): ventriculographic and echocardiographic features in 30 patients. Am J Cardiol. 1979;44:401-412.
3. Arad M, Penas-Lado M, Monserrat L, et al. Gene mutations in apical hypertrophic cardiomyopathy. Circulation. 2005;112:2805-2811.
4. Eriksson MJ, Sonnenberg B, Woo A, et al. Long-term outcome in patients with apical hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;39:638-645.
5. Moro E, D'Angelo G, Nicolosi GL, et al. Long-term evaluation of patients with apical hypertrophic cardiomyopathy. Correlation between quantitative echocardiographic assessment of apical hypertrophy and clinical-electrocardiographic findings. Eur Heart J. 1995;16:210-217.
6. Webb JG, Sasson Z, Rakowski H, et al. Apical hypertrophic cardiomyopathy: clinical follow-up and diagnostic correlates. J Am Coll Cardiol. 1990;15:83-90.
7. Moon J, Shim CY, Ha JW, et al. Clinical and echocardiographic predictors of outcomes in patients with apical hypertrophic cardiomyopathy. Am J Cardiol. 2011;108:1614-1619.
8. Chen CC, Lei MH, Hsu YC, et al. Apical hypertrophic cardiomyopathy: correlations between echocardiographic parameters, angiographic left ventricular morphology, and clinical outcomes. Clin Cardiol. 2011;34:233-238.
9. Fattori R, Biagini E, Lorenzini M, et al. Significance of magnetic resonance imaging in apical hypertrophic cardiomyopathy. Am J Cardiol. 2010;105:1592-1596.
10. Klarich KW, Attenhofer Jost CH, Binder J, et al. Risk of death in long-term follow-up of patients with apical hypertrophic cardiomyopathy. Am J Cardiol. 2013;15:1784-1791.
11. Maron BJ, McKenna WJ, Danielson GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coll Cardiol. 2003;42:1687-1713.
12. Moon JC, Fisher NG, McKenna WJ, et al. Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography. Heart. 2004;90:645-649.
13. Van Der Wall EE, Bax JJ, Schalij MJ. Detection of apical hypertrophic cardiomyopathy; which is the appropriate imaging modality. Int J Cardiovasc Imaging. 2008;24:683-685.
14. Yamada M, Teraoka K, Kawade M, et al. Frequency and distribution of late gadolinium enhancement in magnetic resonance imaging of patients with apical hypertrophic cardiomyopathy and patients with asymmetrical hypertrophic cardiomyopathy: a comparative study. Int J Cardiovasc Imaging. 2009;25:131-138.
15. Suzuki J, Shimamoto R, Nishikawa J, et al. Morphological onset and early diagnosis in apical hypertrophic cardiomyopathy: a long term analysis with nuclear magnetic resonance imaging. J Am Coll Cardiol. 1999;33:146-151.
16. Kim K, Kim H, Hwang I, et al. Myocardial scarring on cardiovascular magnetic resonance in asymptomatic or minimally symptomatic patients with "pure" apical hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14:52.
17. Moon JC, Reed E, Sheppard MN, et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2004;43:2260-2264.
18. Chan RH, Maron B, Olivotto I, et al. Prognostic utility of contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: an international multicenter study. J Am Coll Cardiol. 2012;59:E1570.
19. Gruner C, Care M, Siminovitch K, et al. Sarcomere protein gene mutations in patients with apical hypertrophic cardiomyopathy. Circ Cardiovasc Genet. 2011;4:288-295.
20. Nazarian S, Bluemke DA, Lardo AC, et al. Magnetic resonance assessment of the substrate for inducible ventricular tachycardia in nonischemic cardiomyopathy. Circulation. 2005;112:2821-2825.
21. Spiewak M, Malek LA, Misko J, et al. Comparison of different quantification methods of late gadolinium enhancement in patients with hypertrophic cardiomyopathy. Eur J Radiol. 2010;74:e149-e153.
22. Harrigan CJ, Peters DC, Gibson CM, et al. Hypertrophic cardiomyopathy: quantification of late gadolinium enhancement with contrast-enhanced cardiovascular MR imaging. Radiology. 2011;258:128-133.
23. Moravsky G, Ofek E, Rakowski H, et al. Myocardial fibrosis in hypertrophic cardiomyopathy: accurate reflection of histopathological findings by CMR. JACC Cardiovasc Imaging. 2013;6:587-596.
24. McMahon CJ, Moniotte S, Powell AJ, et al. Usefulness of magnetic resonance imaging evaluation of congenital left ventricular aneurysms. Am J Cardiol. 2007;100:310-315.
25. Cerqueira MD, Weissman NJ, Dilsizian V, et al. Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Int J Cardiovasc Imaging. 2002;18:539-542.
26. Maron MS, Appelbaum E, Harrigan CJ, et al. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy. Circ Heart Fail. 2008;1:184-191.
27. Bruder O, Wagner A, Jensen CJ, et al. Myocardial scar visualized by cardiovascular magnetic resonance imaging predicts major adverse events in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2010;56:875-887.
28. Noureldin RA, Liu S, Nacif MS, et al. The diagnosis of hypertrophic cardiomyopathy by cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2012;14:17.
29. Maron MS. Contrast-enhanced CMR in HCM: What lies behind the bright light of LGE and why it now matters. JACC Cardiovasc Imaging. 2013;6:597-599.
30. Flett AS, Hasleton J, Cook C, et al. Evaluation of techniques for the quantification of myocardial scar of differing etiology using cardiac magnetic resonance. JACC Cardiovasc Imaging. 2011;4:150-156.
31. Amano Y, Takayama M, Fukushima Y, et al. Delayedenhancement MRI of apical hypertrophic cardiomyopathy: assessment of the intramural distribution and comparison with clinical symptoms, ventricular arrhythmias, and cine MRI. Acta Radiol. 2011;52:613-618.
32. Choudhury L, Mahrholdt H, Wagner A, et al. Myocardial scarring in asymptomatic or mildly symptomatic patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2002;40:2156-2164.
33. Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14:13.
34. Harris KM, Spirito P, Maron MS, et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation. 2006;114:216-225.
35. Adabag AS, Maron BJ, Appelbaum E, et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol. 2008;51:1369-1374.
36. Maron MS, Finley JJ, Bos JM, et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation. 2008;118:1541-1549.
37. Lim KK, Maron BJ, Knight BP. Successful catheter ablation of hemodynamically unstable monomorphic ventricular tachycardia in a patient with hypertrophic cardiomyopathy and apical aneurysm. J Cardiovasc Electrophysiol. 2009;20:445-447.
38. Gersh BJ, Maron BJ, Bonow RO, et al. ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;58:e212-e260.
39. Bluemke DA, Yang E. Hypertrophic cardiomyopathy: refining the lens of cardiac magnetic resonance to evaluate late gadolinium enhancement. J Am Coll Cardiol. 2012;60:930-931.
40. Rudolph A, Von Knobelsdorff-Brenkenhoff F, Wassmuth R, et al. Assessment of nonischemic fibrosis in hypertrophic cardiomyopathy: Comparison of gadopentetate dimeglumine and gadobenate dimeglumine for enhanced cardiovascular magnetic resonance imaging. J Magn Reson Imaging. 2014;39:1153-1160.